Artificial intelligence may help predict cardiotoxicity in renal cell carcinoma

Artificial intelligence models can help predict cardiotoxicity risk among patients with renal cell carcinoma treated with VEGF receptor inhibitors, according to study results. Integration of artificial intelligence (AI) models into electronic medical records can help oncologists and other members of the clinical care team identify those who may benefit from cardio-oncology monitoring and treatment, findings presented at International Kidney Cancer Symposium: North America showed. "Further studies comparing differences in outcomes between high-risk ... patients who were referred to cardio-oncology versus patients who were not referred are warranted," Hesham Yasin, MD, clinical fellow at Vanderbilt University Medical Center, and colleagues wrote. Tyrosine kinase inhibitors that target VEGF receptors are standard components of renal cell carcinoma treatment. These agents generally are effective and safe, but they can cause cardiotoxicity risk for an estimated 3% to 8% of patients, according to study background.